Drugs / Metronidazole-DRF2
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01559545 | Mar 2012 → Feb 2013 | Clostridium difficile colitis | Dr. Reddy's Laboratories Limited | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Metronidazole-DRF2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01559545 ↗ |
| Known as | Metronidazole | “Modified release metronidazole (DRF2) 500 mg orally three times a day for 14 days.” NCT01559545 ↗ |
| Route | Oral | “Modified release metronidazole (DRF2) 500 mg orally three times a day for 14 days.” NCT01559545 ↗ |